Refine
Year of publication
Document Type
Language
- English (144)
Is part of the Bibliography
- yes (144) (remove)
Keywords
- diabetic nephropathy (6)
- linagliptin (6)
- pregnancy (6)
- Epigenetics (5)
- Fetal programming (5)
- Pregnancy (5)
- chronic kidney disease (5)
- Endothelin (4)
- Gestational diabetes (4)
- Hypertension (4)
- Placenta (4)
- birth weight (4)
- DPP-4 inhibitors (3)
- Diabetic nephropathy (3)
- Endothelin-1 (3)
- Kidney (3)
- Klotho (3)
- LC-MS/MS (3)
- Metabolomics (3)
- PTH (3)
- acute kidney injury (3)
- albuminuria (3)
- endothelin (3)
- endothelin-converting enzyme (3)
- epigenetics (3)
- genes (3)
- glucocorticoid receptor (3)
- glycaemic control (3)
- hypertension (3)
- insulin resistance (3)
- neutral endopeptidase (3)
- oxidative stress (3)
- Angiogenesis (2)
- Birth weight (2)
- DDP-4 inhibition (2)
- DNA methylation (2)
- DOHaD (2)
- Dipeptidyl peptidase-4 inhibition (2)
- ET-1 (2)
- Endothelin (ET) (2)
- FGF23 (2)
- Free vitamin D (2)
- Gestational diabetes mellitus (2)
- Global DNA methylation (2)
- Glucose tolerance (2)
- Hypermethylation (2)
- Insulin resistance (2)
- Linagliptin (2)
- Lysophosphatidylcholine (2)
- Meta-analysis (2)
- Mortality (2)
- Nitric oxide (2)
- Nutrition (2)
- Renal failure (2)
- TGF-beta 1 (2)
- Type 2 Diabetes (2)
- Vitamin D-binding protein (2)
- angiotensin receptor blockers (2)
- cardiovascular disease (2)
- fetal origins hypothesis (2)
- fetal programming (2)
- genetics (2)
- growth restriction (2)
- kidney (2)
- later health (2)
- low birth weight (2)
- metabolomics (2)
- n-oxPTH (2)
- nutrient transport (2)
- obesity (2)
- offspring (2)
- patterns (2)
- phosphate (2)
- proteomic analysis (2)
- repetitive elements (2)
- telmisartan (2)
- type 2 diabetes (2)
- vascular calcification (2)
- 1,25(OH)(2) vitamin D (1)
- 1,25-Dihydroxyvitamin D-3 (1)
- 11 beta-hydroxysteroid dehydrogenase 2 (1)
- 25-OH vitamin D (1)
- 2k1c renovascular hypertension (1)
- ACE I/D polymorphism (1)
- ACE inhibitors (1)
- ADPKD (1)
- Acute renal failure (1)
- Advanced fetal programming hypothesis (1)
- Angiotensin converting enzyme inhibitor (1)
- Apgar score (1)
- Assays (1)
- BMP4 (1)
- Bioavailable vitamin D (1)
- Biological Assay (1)
- Biomarker (1)
- Biparietal diameter (1)
- Birth Weight (1)
- Blood flow resistance (1)
- Blood pressure (1)
- Brain development (1)
- CKD (1)
- CORM-2 (1)
- Calcium (1)
- Calculated free 25(OH) vitamin D (1)
- Calculated free 25-hydroxyvitamin D (1)
- Cardiac function (1)
- Cardiac ischemia/reperfusion (1)
- Cardiovascular diseases (1)
- Cardiovascular effects (1)
- Chick embryos (1)
- Chicken chorioallantoic membrane (CAM) (1)
- Chicken chorioallantoic membrane (CAM) (1)
- Childhood nephrotic syndrome (1)
- Childhood traits and disorders (1)
- Cholesterol (1)
- Chronic Renal Failure (1)
- Chronic Renal Failure in Children (1)
- Chronic kidney disease (1)
- Clinical (1)
- Clinical study (1)
- Clinical trials (1)
- Consortium (1)
- Contrast induced acute kidney injury (1)
- Coronary angiography (1)
- Cortisol Maternal cortisol (1)
- Cortisol vertical bar metabolism (1)
- D-galactosamine (1)
- DPP-4 (1)
- DPP-4 inhibition (1)
- DPP-4 inhibitor (1)
- DPP-IV inhibitor (1)
- DPP4 inhibition (1)
- Developmental programming (1)
- Diabetes (1)
- Diabetic cardiomyopathy (1)
- Dialysis patients (1)
- Dipeptidyl peptidase 4 inhibitor (1)
- Dipeptidyl peptidase IV (1)
- Dipeptidylpeptidase-4 (1)
- Directly measured free vitamin D (1)
- ETA (1)
- ETB (1)
- ETB receptor-deficient mouse (1)
- Endothelial nitric oxide synthase (1)
- Endothelin receptor antagonists (1)
- Endothelin-1 transgenic mice (1)
- Et-1 (1)
- FASN (1)
- Fetal development (1)
- Fibrosis (1)
- Free 25(OH) vitamin D (1)
- Furosemide (1)
- GLP-1 (1)
- GLP-1 and SDF-1a (1)
- GLP-1 receptor (1)
- GLUT1 XbaI gene polymorphism (1)
- Gene polymorphism (1)
- Genetic polymorphism (1)
- Genetics (1)
- Global (1)
- Glp1r(-/-) mice (1)
- Gut microbiota (1)
- HNRNPA1 (1)
- HSD11B2[CA]n polymorphism (1)
- Head circumference (1)
- Heart failure (1)
- Heart weight (1)
- Hemodialysis (1)
- High osmolarity (1)
- High-fat-sucrose-salt diet (1)
- Hypoxia (1)
- Infarct size (1)
- Inflammation (1)
- Influenza virus (1)
- Kaplan-Meier plot (1)
- Kidney Transplantation (1)
- Kidney weight (1)
- Kynurenine (1)
- Lens (1)
- Lipopolysaccharides (LPS) (1)
- Lipopolysaccharides (LPS) (1)
- Long term health (1)
- Longitudinal (1)
- Loop diuretics (1)
- Major adverse kidney event (1)
- Maternal folate treatment (1)
- Measured free 25-hydroxyvitamin D (1)
- Methylation (1)
- Mice (1)
- Myocardial infarction (1)
- Myocardial ischemia (1)
- NGAL (1)
- NR3C1 gene (1)
- Natriuretic peptides (1)
- Offspring (1)
- Orai1 (1)
- Outcome (1)
- Oxidation (1)
- PCaaC38:6 (1)
- PI3K (1)
- PKB/Akt (1)
- PKM2 (1)
- Paternal programming (1)
- Paternal, maternal, sex differences (1)
- Pax6 (1)
- Pharmacokinetics (1)
- Phosphate (1)
- Phosphatidylcholine acyl-alkyl C 32:1 (1)
- Preeclampsia (1)
- Preinterventional biomarker (1)
- Preterm birth (1)
- Preterm delivery (1)
- Proline (1)
- Pulmonary arterial hypertension (1)
- Radiocontrast media-induced nephropathy (1)
- Rats (1)
- Reference intervals (1)
- Relaxin (1)
- Renin-angiotensin system (1)
- Renin-angiotensin-aldosterone system (1)
- Resistant starch (1)
- Retina (1)
- SREBP-1c (1)
- SU5416 (1)
- Safety (1)
- Serum intact-parathyroid hormone level (1)
- Sexual dimorphism (1)
- Shan He Jian Fei Granules (SHJFG) (1)
- Side effects (1)
- Single nucleotide polymorphism (1)
- Small for gestational age (1)
- Stillbirth (1)
- Stroke (1)
- Stromal cell-derived factor-1 (1)
- TRPV5 (1)
- TRPV6 (1)
- Thrifty phenotype (1)
- Total 25(OH) vitamin D (1)
- Umbilical artery Doppler (1)
- Urinary ET-1 (1)
- Vitamin D (1)
- Vitamin D binding protein (1)
- Vitamin D deficiency (1)
- Water and salt retention (1)
- YB-1 (1)
- acute liver failure (1)
- adiponectin (1)
- alleles (1)
- angiotensin (1-7) (1)
- angiotensin II (1)
- antidiabetic drug (1)
- asymmetric dimethylarginine (ADMA) (1)
- atherosclerosis (1)
- auditory neurons (1)
- biobanks (1)
- bioinformatics (1)
- biomarkers (1)
- biomarkers of renal failure (1)
- birthweight (1)
- bladder cancer cells (1)
- blood biomarker (1)
- blood pressure (1)
- calbindin D9k (1)
- calcitriol (1)
- calcium (1)
- calcium transport (1)
- capillary blood (1)
- cardiac progenitor migration and differentiation (1)
- cardiac remodeling (1)
- cardiac surgery (1)
- cardiometabolic diseases (1)
- cardiovascular diseases (1)
- cardiovascular-disease (1)
- chick embryo (1)
- children (1)
- chronic renal failure (1)
- chronic renal failure in children (1)
- clear cell renal cell carcinoma (1)
- clinical studies (1)
- clinical trial (1)
- clusterin (1)
- collagen I (1)
- comparison (1)
- complication (1)
- contrast-induced nephropathy (1)
- cyclic-GMP (1)
- diabetes (1)
- diabetic control (1)
- differentially expressed genes (1)
- differentiation (1)
- disease (1)
- disproportional intrauterine growth retardation (1)
- distal convoluted tubule (1)
- duration of gestation (1)
- eNOS (1)
- early diagnosis (1)
- endothelial dysfunction (1)
- endothelin receptors (1)
- failure (1)
- fasting blood glucose (1)
- fatty liver (1)
- fetal programing (1)
- fetal sex (1)
- fetus (1)
- fibrosis (1)
- filter paper (1)
- foot and mouth disease (HFMD) (1)
- genome-wide association study (1)
- genotype (1)
- gliptins (1)
- glomerular arterioles (1)
- glycemic control (1)
- glycemic control during pregnancy (1)
- guanylate cyclase (1)
- haemodialysis (1)
- hand (1)
- heart tube (1)
- heart-failure (1)
- heart-type fatty acid binding protein (1)
- hemodialysis (1)
- hepatic impairment (1)
- high salt (1)
- high-fat diet (1)
- hypotension (1)
- in situ hybridization (1)
- incretins (1)
- independent activation (1)
- intervention (1)
- intrauterine (1)
- intrauterine fetal growth (1)
- ischemia reperfusion injury (1)
- kidney injury molecule 1 (1)
- kidney transplantation (1)
- large sample size studies (1)
- leptin (1)
- lipid (1)
- low birth weight (LBW) (1)
- lower respiratory tract infections (LRTIs) (1)
- macroarray (1)
- matrix metalloproteinases (1)
- meta-analysis (1)
- metabolism (1)
- molecule-1 KIM-1 (1)
- mortality (1)
- mothers (1)
- mouse (1)
- nephrin (1)
- neutrophil gelatinase-associated lipocalin (1)
- new analysis method (1)
- nitric oxide (1)
- nitric-oxide (1)
- one dot two development signals (ODTDS) dot blot (1)
- osteoblast (1)
- osteopontin (1)
- osterix (1)
- outcome (1)
- oxidation (1)
- p-AKT (1)
- p-mTOR (1)
- parathyroid hormone (1)
- paternal programming (1)
- phosphatidylcholine acyl-alkyl C 32:1 (1)
- placenta (1)
- pneumonia (1)
- polycystic kidney disease (1)
- pregnancy induced diabetes (1)
- preterm delivery (1)
- proline (1)
- protein quantification (1)
- proteinuria (1)
- pulmonary hypertension (1)
- pulmonary-hypertension (1)
- ramipril (1)
- rapid detection method (1)
- reactive oxygen species (1)
- renal dysfunction (1)
- renal haemodynamics (1)
- renal impairment (1)
- renovascular hypertension (1)
- resistin (1)
- retinol (1)
- retinol-binding protein 4 (1)
- safety efficacy (1)
- scrub typhus (1)
- signal-transduction system (1)
- single nucleotide polymorphism (1)
- spermatogenesis (1)
- sudden death (1)
- telbivudine (1)
- therapeutic target (1)
- thymosin beta 4 (1)
- tissue inhibitior of metalloproteinases 1 (1)
- total glycated hemoglobin (1)
- total glycosylated hemoglobin (1)
- transgenerational effects (1)
- transient receptor potential (1)
- transmission of hepatitis B virus (HBV) (1)
- ultrasound (1)
- urinary biomarker (1)
- vascular smooth muscle cells (1)
- vesicular trafficking (1)
- weight loss (1)
- western blot (1)
Institute
- Institut für Ernährungswissenschaft (111)
- Institut für Biochemie und Biologie (9)
- Department Sport- und Gesundheitswissenschaften (8)
- Mathematisch-Naturwissenschaftliche Fakultät (8)
- Institut für Chemie (2)
- Institut für Geowissenschaften (1)
- Institut für Informatik und Computational Science (1)
- Institut für Mathematik (1)
- UP Transfer (1)
Aims:This study aims to investigate the relationship between plasma endothelin-1 (ET-1) concentrations, ET-1 gene polymorphisms in loci rs5370, rs1630736, 3A/4A and clinical features of primary nephrotic syndrome (NS) in children.
Materials and methods: Thirty-six children with primary NS were selected as case group, and 94 healthy children were selected as control group. All subjects were genotyped for three single nucleotide polymorphisms (SNPs) (rs5370, rs10478694 [3A4A) and rs 1630736) in the ET-1 gene by gene sequencing. The plasma ET-1 concentrations were measured using a radio-immunoassay.
Key findings: Plasma ET-1 concentrations were higher in NS patients (P = 0.007) as compared to healthy children. The allele frequencies between control and NS patients were significantly different only with respect to the rs10478694 SNP of the ET-1 gene. The allele frequencies between control and NS patients for the rs5370 SNP showed a trend towards difference (P = 0.057). Plasma cholesterol in NS patients is associated with both: the Cl genotype in locus rs5370 and the 3A4A genotype in locus rs10478694 (P < 0.05 in both cases).
Significance: The ET systems might play a disease modifying role in pediatric NS. Plasma cholesterol, a hallmark of NS. seems to be associated with genetic variations within the human ET-1 gene. (C) 2014 Elsevier Inc. All rights reserved.
Background: The multidrug transporter P-glycoprotein (PGP) is expressed in the human placenta. In particular the C3435T ABCB1 polymorphism was associated with altered tissue expression of PGP in the human placenta. However, the potential functional impact of this polymorphism on the offspring is unknown so far.
Methods: We analyzed the impact of the ABCB1/C3435T polymorphism on fetal growth in 262 mother/child pairs. Fetal growth was assessed by differential ultrasound examination of the fetal body prior to birth and by measuring birth weight.
Results: The maternal ABCB1/C3435T polymorphism showed no trend for an association with birth weight or any ultrasound parameter describing late gestational fetal body shape. Genotyping the newborns, however, demonstrated that newborns carrying two copies of the T allele had a birth weight of 3176.39 g, whereas CT and CC newborns had a birth weight of 3345.04 g (p = 0.022). Adjusting for gestational age at delivery, child's gender, maternal BM1, maternal age and body weight at delivery confirmed this finding (p = 0.009). Considering gestational day of late ultrasound examination, gestational age at delivery, child's gender, maternal BMI, maternal age and maternal body weight at delivery, the fetal ABCB1/C3435T genotype revealed likewise a significant negative correlation with abdominal diameter and abdominal circumference (R-2 = 0.538, p = 0.010 and R-2 = 0.534, p = 0.005, respectively).
Conclusions: Low birth weight may be a risk factor for cardiovascular diseases in later life. The fetal ABCB1/C3435T gene polymorphism may contribute to this risk. Since PGP controls transport of various biological agents, we suggest that PGP is involved in the transport of biological agents to the fetus that are important for normal fetal growth.
Being born large for gestational age is associated with increased global placental DNA methylation
(2020)
Being born small (SGA) or large for gestational age (LGA) is associated with adverse birth outcomes and metabolic diseases in later life of the offspring. It is known that aberrations in growth during gestation are related to altered placental function. Placental function is regulated by epigenetic mechanisms such as DNA methylation. Several studies in recent years have demonstrated associations between altered patterns of DNA methylation and adverse birth outcomes. However, larger studies that reliably investigated global DNA methylation are lacking. The aim of this study was to characterize global placental DNA methylation in relationship to size for gestational age. Global DNA methylation was assessed in 1023 placental samples by LC-MS/MS. LGA offspring displayed significantly higher global placental DNA methylation compared to appropriate for gestational age (AGA; p<0.001). ANCOVA analyses adjusted for known factors impacting on DNA methylation demonstrated an independent association between placental global DNA methylation and LGA births (p<0.001). Tertile stratification according to global placental DNA methylation levels revealed a significantly higher frequency of LGA births in the third tertile. Furthermore, a multiple logistic regression analysis corrected for known factors influencing birth weight highlighted an independent positive association between global placental DNA methylation and the frequency of LGA births (p=0.001).
Being born large for gestational age is associated with increased global placental DNA methylation
(2020)
Being born small (SGA) or large for gestational age (LGA) is associated with adverse birth outcomes and metabolic diseases in later life of the offspring. It is known that aberrations in growth during gestation are related to altered placental function. Placental function is regulated by epigenetic mechanisms such as DNA methylation. Several studies in recent years have demonstrated associations between altered patterns of DNA methylation and adverse birth outcomes. However, larger studies that reliably investigated global DNA methylation are lacking. The aim of this study was to characterize global placental DNA methylation in relationship to size for gestational age. Global DNA methylation was assessed in 1023 placental samples by LC-MS/MS. LGA offspring displayed significantly higher global placental DNA methylation compared to appropriate for gestational age (AGA; p<0.001). ANCOVA analyses adjusted for known factors impacting on DNA methylation demonstrated an independent association between placental global DNA methylation and LGA births (p<0.001). Tertile stratification according to global placental DNA methylation levels revealed a significantly higher frequency of LGA births in the third tertile. Furthermore, a multiple logistic regression analysis corrected for known factors influencing birth weight highlighted an independent positive association between global placental DNA methylation and the frequency of LGA births (p=0.001).
The present study aimed to identify new key genes as potential biomarkers for the diagnosis, prognosis or targeted therapy of clear cell renal cell carcinoma (ccRCC). Three expression profiles (GSE36895, GSE46699 and GSE71963) were collected from Gene Expression Omnibus. GEO2R was used to identify differentially expressed genes (DEGs) in ccRCC tissues and normal samples. The Database for Annotation, Visualization and Integrated Discovery was utilized for functional and pathway enrichment analysis. STRING v10.5 and Molecular Complex Detection were used for protein-protein interaction (PPI) network construction and module analysis, respectively. Regulation network analyses were performed with the WebGestal tool. UALCAN web-portal was used for expression validation and survival analysis of hub genes in ccRCC patients from The Cancer Genome Atlas (TCGA). A total of 65 up- and 164 downregulated genes were identified as DEGs. DEGs were enriched with functional terms and pathways compactly related to ccRCC pathogenesis. Seventeen hub genes and one significant module were filtered out and selected from the PPI network. The differential expression of hub genes was verified in TCGA patients. Kaplan-Meier plot showed that high mRNA expression of enolase 2 (ENO2) was associated with short overall survival in ccRCC patients (P=0.023). High mRNA expression of cyclin D1 (CCND1) (P<0.001), fms related tyrosine kinase 1 (FLT1) (P=0.004), plasminogen (PLG) (P<0.001) and von Willebrand factor (VWF) (P=0.008) appeared to serve as favorable factors in survival. These findings indicate that the DEGs may be key genes in ccRCC pathogenesis and five genes, including ENO2, CCND1, PLT1, PLG and VWF, may serve as potential prognostic biomarkers in ccRCC.
Biomarkers for the prediction of mortality and morbidity in patients with renal replacement therapy
(2011)
The mortality of end-stage renal disease (ESRD) patients on dialysis remains high despite great improvement of dialysis technologies in the past decades.
These patients die due to infectious diseases (mainly sepsis), cardiovascular diseases such as myocardial infarction, heart failure, stroke, and, in particular, sudden cardiac death. End stage renal disease is a complex condition, where the failure of kidney function is accompanied by numerous metabolic changes affecting almost all organ systems of the human body. Many of the biomarker characteristics of the individually affected organ systems have been associated with adverse outcomes. These biomarkers are different in patients with ESRD compared to the general population in the prediction of morbidity and mortality. Biomarker research in this field should aim to identify patients at risk for the different disease entities.
Traditional biomarkers such as CRP, BNP, and troponins as well as new biomarkers such as fetuin, CD 154, and relaxin were analyzed in patients on dialysis. We will include observational as well as prospective clinical trials in this review. Furthermore, we will also discuss proteomics biomarker studies. The article assess the potential diagnostic value of different biomarkers in daily clinical practice as well as their usefulness for clinical drug development in end stage renal disease patients.
Background: Low birthweight is an independent risk factor of glucose intolerance and type 2 diabetes in later life. Genetically determined insulin resistance and subsequently impaired glucose uptake might explain both reduced fetal growth and elevated blood glucose. The glucose transporter 1 (GLUT!) plays an important role for fetal glucose uptake as well as for maternal-fetal glucose transfer, and it has been associated with insulin resistance in adults. The present study hypothesized that the common fetal GLUT1 XbaI polymorphism might reduce fetal insulin sensitivity and/or glucose supply in utero, thus affecting fetal blood glucose and fetal growth.
Methods: A genetic association study was conducted at the obstetrics department of the Charite University Hospital, Berlin, Germany. 119.1 white women were included after delivery, and all newborns were genotyped for the GLUT1 XbaI polymorphism. Total glycosylated hemoglobin was quantified, serving as a surrogate of glycemia during the last weeks of pregnancy.
Results: The analysis of this large population showed no significant differences in fetal glycosylated hemoglobin or birthweight for the different fetal GLUT1 XbaI genotypes. Only newborns carrying the mutated allele show the previously published inverse association between birthweight and glycosylated hemoglobin.
Conclusions: The results suggest that there is no prenatal effect of the fetal GLUT1 XbaI polymorphism on fetal insulin sensitivity, intrauterine fetal glucose supply or fetal growth. However, the polymorphism seems to modulate the inverse interaction between birthweight and fetal glycemia.
Background: Despite the beneficial effects of type 4 dipeptidyl peptidase (DPP-4) inhibitors on glucose levels, its effects on diabetic nephropathy remain unclear.
Method: This study examined the long-term renoprotective effects of DPP-4 inhibitor linagliptin in db/db mice, a model of type 2 diabetes.
Results were compared with the known beneficial effects of renin-angiotensin system blockade by enalapril. Ten-week-old male diabetic db/db mice were treated for 3 months with either vehicle (n = 10), 3 mg linagliptin/kg per day (n = 8), or 20 mg enalapril/kg per day (n = 10). Heterozygous db/m mice treated with vehicle served as healthy controls (n = 8). Results: Neither linagliptin nor enalapril had significant effects on the parameters of glucose metabolism or blood pressure in diabetic db/db mice. However, linagliptin treatment reduced albuminuria and attenuated kidney injury. In addition, expression of podocyte marker podocalyxin was normalized. We also analysed DPP-4 expression by immunofluorescence in human kidney biopsies and detected upregulation of DPP-4 in the glomeruli of patients with diabetic nephropathy, suggesting that our findings might be of relevance for human kidney disease as well.
Conclusion: Treatment with DPP-4 inhibitor linagliptin delays the progression of diabetic nephropathy damage in a glucose-independent and blood-pressure-independent manner. The observed effects may be because of the attenuation of podocyte injury and inhibition of myofibroblast transformation.
Background: Previous studies have shown that BMP4 may play an important part in the development of auditory neurons (ANs), which are degenerated in sensorineural hearing loss. However, whether BMP4 can promote sensory fate specification from mesenchymal stromal cells (MSCs) is unknown so far.
Methods: MSCs isolated from Sprague-Dawley (SD) rats were confirmed by expression of MSC markers using flow cytometry and adipogenesis/osteogenesis using differentiation assays. MSCs treated with a complex of neurotrophic factors (BMP4 group and non-BMP4 group) were induced into auditory neuron-like cells, then the differences between the two groups were analyzed in morphological observation, cell growth curve, qRT-PCR, and immunofluorescence.
Results: Flow cytometric analysis showed that the isolated cells expressed typical MSC surface markers. After adipogenic and osteogenic induction, the cells were stained by oil red O and Alizarin Red. The neuronal induced cells were in the growth plateau and had special forms of neurons. In the presence of BMP4, the inner ear genes NF-M, Neurog1, GluR4, NeuroD, Calretinin, NeuN, Tau, and GATA3 were up-regulated in MSCs.
Conclusions: MSCs have the capacity to differentiate into auditory neuron-like cells in vitro. As an effective inducer, BMP4 may play a key role in transdifferentiation.